KM Financial Solutions | CORRECTED-FOCUS-Novartis wins Medicaid approval for new sickle cell drug in key U.S. states
59187
post-template-default,single,single-post,postid-59187,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-child-theme-ver-1.0.0,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive
 

CORRECTED-FOCUS-Novartis wins Medicaid approval for new sickle cell drug in key U.S. states

CORRECTED-FOCUS-Novartis wins Medicaid approval for new sickle cell drug in key U.S. states

Novartis AG has secured Medicaid
coverage for a pricey new sickle cell disease therapy in two
U.S. states just weeks after winning U.S. approval, following an
early campaign to convince local officials of its value,
according to a company executive and a Reuters review of public
filings.

No Comments

Sorry, the comment form is closed at this time.